T ‐cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3‐ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Source Type: research

Related Links:

Condition:   Acute Myeloid Leukemia, Adult Intervention:   Drug: Midostaurin Sponsors:   Sebastian Scholl, PD Dr. med.;   Ludwig-Maximilians - University of Munich Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 11 May 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): Anthony M. Hunter, David A. SallmanAbstractMutations in the essential tumor suppressor gene, TP53, are observed in only 5-10% of acute myeloid leukemia (AML) cases, but are highly associated with therapy-related AML and cases with complex karyotype. The mutational status of TP53 is a critical prognostic indicator, with dismal outcomes consistently observed across studies. Response rates to traditional cytotoxic chemotherapy are poor and long-term survival after allogeneic hematopoietic stem cell transplant is ra...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Abstract Acute myeloid leukemia (AML) is a heterogeneous malignancy of hematopoietic stem cells with poor clinical outcome despite recent improvements in chemotherapy and stem cell transplantation regimens. Thus, new therapeutic agents are urgently needed in order to prolong the disease-free survival of AML patients in clinic. Here, we report that BBI608 is highly active against diverse AML cell lines in vitro and primary samples obtained from patients with AML ex vivo, as well as effective in vivo in AML xenograft models. Meanwhile, the anti-AML property of BBI608 is closely associated with the inhibition of Stat...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
This article aims to provide an update on the knowledge that an internist should know for the practical management of myelodysplastic syndromes in 2019. PMID: 31054780 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Authors: Guo Z, Liu XD, Chen HR Abstract [This corrects the article DOI: 10.18632/oncotarget.22612.]. PMID: 31040914 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: Available online 2 May 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Tzu-yin Lin, Yanjun Zhu, Yuanpei Li, Hongyong Zhang, Ai-Hong Ma, Qilai Long, James Keck, Kit S. Lam, Chong-xian Pan, Brian A. JonasAbstractPatients with acute myeloid leukemia have a very poor prognosis related to a high rate of relapse and drug-related toxicity. The ability of leukemia stem cells (LSCs) to survive chemotherapy is primarily responsible for relapse, and eliminating LSCs is ultimately essential for cure. We developed novel disulfide-crosslinked CLL1-targeting micelles (DC-CTM), which can deliver ...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
With the development of allogeneic hematopoietic stem cell transplantation (allo-SCT) from alternative donor sources, including unrelated donors, umbilical cord blood, and haploidentical transplantation (haploSCT), the clinical application of autologous hematopoietic SCT (ASCT) has decreased.1 However, the clinical outcomes associated with ASCT have improved over time. European scholars retrospectively analyzed the survival outcomes of ASCT in 809 patients with acute myeloid leukemia (AML) in the first complete remission (CR1) and found that the 2-year leukemia-free survival (LFS) and overall survival (OS) rates were as hi...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: Review Source Type: research
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a distinct entity defined by the World Health Organization (WHO) in 2008, by the presence of multilineage dysplasia (MLD), and/or myelodysplastic syndrome (MDS)-related cytogenetics, and/or a history of MDS or MDS/myeloproliferative neoplasm (MPN) [1]. In the 2016 WHO classification, AML-MRC was preserved as a distinct entity, with some minor revisions in MDS-related cytogenetics [2]. A majority of the patients in studies reporting that the prognosis of AML-MRC was worse than that of AML-not otherwise specified (NOS) [3 –8] had undergone chemothe...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
EBMT Abstract Deletion 5q or monosomy 5 (-5/5q-) in acute myeloid leukemia is a common high-risk feature referred to allogeneic stem cell transplantation. However, -5/5q- is frequently associated with other high-risk cytogenetic aberrations such as complex karyotype, monosomal karyotype, monosomy 7 (-7), or 17p abnormalities (abn (17p)), the significance of which is unknown. In order to address this question, we studied adult patients with acute myeloid leukemia harboring -5/5q- having their first allogeneic transplantation between 2000 and 2015. Five hundred and one patients with -5/5q- have been analyzed. Three...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes Intervention:   Drug: ONC201 Sponsor:   Vijaya Bhatt Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants